
CLAIMS:-


1. A compound of the formula:




,

wherein:

A is:



or




;

R_1 to R_9 are independently C, N, O or S;

Q is independently selected from $C_{1\text{-}6}$alkyl, halo, $C_{0\text{-}6}$alkyl carboxylic acid, amino, hydroxy and $C_{1\text{-}6}$alkoxy;

n is 0, 1, 2, 3 or 4; and

X is -OH or 

,

or a pharmacologically acceptable salt, stereoisomer, diastereomer, enantiomer, racemate, hydrate and/or solvate thereof,

wherein when X is -OH, A cannot be unsubstituted phenyl.

2. The compound according to claim 1, wherein Q is independently selected from $-CH_3$, -C(O)OH, -F, $-NH_2$, -OH and $-OCH_3$.


3. The compound according to claim 1 or claim 2, wherein R_5 to R_9 are independently C or N.

4. The compound according to any one claims 1 to 3, wherein n is 0, 1 or 2.

5. The compound according to any one of claims 1 to 4, wherein the $C_{0\text{-}6}$alkyl carboxylic acid is carboxylic acid.


6. The compound according to any one of claims 1 to 5, wherein X is -OH.

7. The compound according to any one of claims 1 to 6, wherein X is




.


8. The compound according to any one of claims 1 to 6, wherein the compound is selected from the group consisting of:




(**P5**),




(**P8**),




(**P9**),




(**P11**),




(**P22**),




(**P26**),




(**P40**),




(**P41**)




(**P47**),




(**P3**),




(**P49**),




(**P46**),




(**P48**),




(**P50**),




(**P1**),








(**P6**),



(**P33**),




(**P38**),


(**P42**),

(**P43**),

(**P44**),

(**P45**) and

(**P4**),

or a pharmacologically acceptable salt, glucuronide, stereoisomer, diastereomer, enantiomer, racemate, hydrate and/or solvate thereof.

9. The compound according to any one of claims 1 to 5 or 7, wherein the compound is:


(**P104**).

or a pharmacologically acceptable salt, stereoisomer, diastereomer, enantiomer, racemate, hydrate and/or solvate thereof.

10. A pharmaceutical composition comprising the compound according to any one of claims 1 to 9 and a pharmaceutically acceptable excipient.

11. Use of a compound according to any one of claim 1 to 9 for the manufacture of a medicament for the prophylactic or therapeutic treatment of kidney and/or liver disease.

12. The use according to claim 11 wherein the medicament prevents, reduces or slows the progression of kidney and/or liver fibrosis.


13. The use according to claim 11, wherein the medicament reduces established kidney and/or liver fibrosis.

14. The use according to claim 11, wherein the medicament prevents, reduces or slows renal tubular cell death.

15. The use according to claim 11, wherein the medicament prevents, reduces or slows accumulation of hepatic fat.

16. The use according to claim 11, wherein the medicament restores normal tissue architecture.

17. A compound of the formula:



,

or a pharmacologically acceptable salt, glucuronide, stereoisomer, diastereomer, enantiomer, racemate, hydrate and/or solvate thereof.